EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Elongation of Very Long-Chain Fatty Acids (ELOVL) in Atopic Dermatitis and the Cutaneous Adverse Effect AGEP of Drugs

Markus Blaess iD, René Csuk iD, Teresa Schätzl, Hans-Peter Deigner iD

International Journal of Molecular Sciences · 28.08.2024 · 25 (17) · 9344

DOI: 10.3390/ijms25179344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.08.2024. Verfasst von Markus Blaess und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Precision Medicine, Medical and Life Sciences Faculty, Furtwangen University, Jakob-Kienzle-Str. 17, D-78054 Villingen-Schwenningen, Ger…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Ceramides, Fatty Acids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Precision Medicine, Institute for Applied Research (IAF), Furtwangen University, VS-Schwenningen, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a common inflammatory skin disease, in particular among infants, and is characterized, among other things, by a modification in fatty acid and ceramide composition of the skin’s stratum corneum. Palmitic acid and stearic acid, along with C16-ceramide and 2-hydroxy C16-ceramide, occur strikingly in AD. They coincide with a simultaneous decrease in very long-chain ceramides and ultra-long-chain ceramides, which form the outermost lipid barrier. Ceramides originate from cellular sphingolipid/ceramide metabolism, comprising a well-orchestrated network of enzymes involving various ELOVLs and CerSs in the de novo ceramide synthesis and neutral and acid CERase in degradation. Contrasting changes in long-chain ceramides and very long-chain ceramides in AD can be more clearly explained by the compartmentalization of ceramide synthesis. According to our hypothesis, the origin of increased C16-ceramide and 2-hydroxy C16-ceramide is located in the lysosome. Conversely, the decreased ultra-long-chain and very long-chain ceramides are the result of impaired ELOVL fatty acid elongation. The suggested model’s key elements include the lysosomal aCERase, which has pH-dependent long-chain C16-ceramide synthase activity (revaCERase); the NADPH-activated step-in enzyme ELOVL6 for fatty acid elongation; and the coincidence of impaired ELOVL fatty acid elongation and an elevated lysosomal pH, which is considered to be the trigger for the altered ceramide biosynthesis in the lysosome. To maintain the ELOVL6 fatty acid elongation and the supply of NADPH and ATP to the cell, the polyunsaturated PPARG activator linoleic acid is considered to be one of the most suitable compounds. In the event that the increase in lysosomal pH is triggered by lysosomotropic compounds, compounds that disrupt the transmembrane proton gradient or force the breakdown of lysosomal proton pumps, non-HLA-classified AGEP may result.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicCeramidesFatty AcidsHumansFatty Acid ElongasesSkinAnimals

Stichwörter der Autor:innen

AGEPELOVLatopic dermatitisbasic therapyceramidecutaneous adverse effectseczemafatty acid elongationlysosomelysosomotropism

Substanzen

CeramidesFatty AcidsFatty Acid Elongases

Autor:innen und Institutionen

  • Institute of Precision Medicine, Medical and Life Sciences Faculty, Furtwangen University, Jakob-Kienzle-Str. 17, D-78054 Villingen-Schwenningen, Germany.
  • Organic Chemistry, Martin-Luther University Halle-Wittenberg, Kurt-Mothes, Str. 2, D-06120 Halle (Saale), Germany.
  • Fraunhofer Institute IZI, Leipzig, EXIM Department, Schillingallee 68, D-18057 Rostock, Germany.
  • Faculty of Science, Tuebingen University, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany.

ORCID-Profile: Markus Blaess, René Csuk, Hans-Peter Deigner

Förderung

  • Institute of Precision Medicine
  • Institute for Applied Research (IAF)
  • Furtwangen University, VS-Schwenningen, Germany

Zitieren

APA

Blaess, M., Csuk, R., Schätzl, T., & Deigner, H. P. (2024). Elongation of Very Long-Chain Fatty Acids (ELOVL) in Atopic Dermatitis and the Cutaneous Adverse Effect AGEP of Drugs. International Journal of Molecular Sciences, 25(17), 9344. https://doi.org/10.3390/ijms25179344

Vancouver

Blaess M, Csuk R, Schätzl T, Deigner HP. Elongation of Very Long-Chain Fatty Acids (ELOVL) in Atopic Dermatitis and the Cutaneous Adverse Effect AGEP of Drugs. International Journal of Molecular Sciences. 2024;25(17):9344. doi:10.3390/ijms25179344

BibTeX
@article{Blaess2024,
  author = {Blaess, Markus and Csuk, René and Schätzl, Teresa and Deigner, Hans-Peter},
  title = {Elongation of Very Long-Chain Fatty Acids (ELOVL) in Atopic Dermatitis and the Cutaneous Adverse Effect AGEP of Drugs},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {17},
  pages = {9344},
  doi = {10.3390/ijms25179344}
}
Kostenlos starten →